Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT00555555
Other study ID # GBI 07-03
Secondary ID
Status Active, not recruiting
Phase Phase 4
First received
Last updated
Start date September 2007
Est. completion date March 2029

Study information

Verified date August 2023
Source Grifols Biologicals, LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To assess the efficacy of FVIII/VWF Complex (Human), Alphanate® as replacement therapy in preventing excessive bleeding in subjects with congenital Type 3 von Willebrand Disease (VWD) who undergo surgical procedures.


Description:

For the treatment of surgical procedures the intended dose of Alphanate® will be given as a single dose or as multiple doses over several days, depending on the clinical situation, and according to the Full Prescribing Information guideline and the investigator's judgment. For each treated event, the subject's treatment period will be finished when, in the opinion of the local Investigator, the participating subject would not benefit from further infusions of the study concentrate.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 15
Est. completion date March 2029
Est. primary completion date December 2028
Accepts healthy volunteers No
Gender All
Age group 7 Years and older
Eligibility Inclusion Criteria: 1. Male or female 7 years of age or older 2. The subject has been diagnosed of inherited VWD of Type 3 as determined by subject's medical records. 3. The subject needs a surgical procedure (at least 10 surgical procedures have to be considered as "Major" according to the criteria of the protocol). 4. The subject is expected to respond to exogenously administered FVIII/VWF according to Investigator's judgment. 5. The subject freely gives written informed consent. Patients who are not legally permitted to provide written consent must sign a form of assent for study participation, and written consent must be provided by a parent or legal guardian. Exclusion Criteria: 1. The subject has been diagnosed of acquired VWD. 2. The subject is known to have history of intolerance to any Alphanate® containing substance. 3. The subject is known to have history of anaphylactic reaction(s) to blood or blood components. 4. Liver function tests (AST, ALT, bilirubin) > 2.5 x upper limit of normal (ULN). 5. Renal function test (creatinine, BUN) > 1.5 x ULN. 6. The subject is known or suspected to have present or past inhibitor activity (antibodies) directed against FVIII or VWF. 7. The subject is known to abuse alcohol or illicit drug use within the past 12 months. 8. The subject is participating in another clinical study involving an investigational treatment, or participated within the past 4 weeks (except if the patient is participating in another Alphanate® study). Studies consisting of data and blood sampling collections on a regular or long-term basis are exempt from this exclusion. 9. The subject is unlikely to adhere to the protocol requirements of the study.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Alphanate SD/HT
A general guideline based on the product Full Prescribing Information is recommended with a maximum dose of 80 VWF:RCof IU/kg. The number of administrations before, during, and after the surgery procedure depends on the subject's clinical condition and the type of surgery itself. Single administrations or multiple doses may be appropriate. The dose of Alphanate® administered to each subject will be recorded as IU of VWF:RCof and also as IU of FVIII:C. The lot number for each vial of concentrate administered will also be recorded.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Grifols Biologicals, LLC

Outcome

Type Measure Description Time frame Safety issue
Primary Assess the efficacy of FVIII/VWF Complex (Human), Alphanate® as replacement therapy in preventing excessive bleeding in subjects with congenital Type 3 von Willebrand Disease (VWD) who undergo surgical procedures (mostly major surgeries). 30 days
Secondary To assess the Day 0 (surgery day) and Day 1 (post-surgery day) treatment outcomes of each surgical procedure, rated by the investigator using a 2-point verbal rating scale. 1 Day
Secondary Assessment of Safety and Tolerability 30 days
See also
  Status Clinical Trial Phase
Withdrawn NCT01651468 - The Effect of the Nutraceutical "Hemofix" on the Coagulation System N/A
Terminated NCT00178542 - Change in Thrombin Generation Potential and Thromboelastography During the Menstrual Cycle N/A
Completed NCT02552576 - Study of Voncento® in Subjects With Von Willebrand Disease Phase 4
Recruiting NCT02869074 - Molecular and Clinical Profile of Von Willebrand Disease in Spain
Completed NCT01602419 - Surveillance of Safety and Efficacy of Wilate in Patients With Von Willebrand Disease
Completed NCT01224808 - Extension Study of Biostate in Subjects With Von Willebrand Disease Phase 3
Withdrawn NCT00694785 - A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of ARC1779 Injection in Patients With Von Willebrand Disease Type 2B Phase 2
Completed NCT00805051 - Acquired Von Willebrand Syndrome in Severe Aortic Stenosis N/A
Completed NCT00168090 - Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD) Phase 4
Completed NCT02246881 - A Study to Compare the Pharmacokinetics and Safety of Current Factor VIII Concentrate and Optivate® in Haemophilia A. Phase 3
Completed NCT04657887 - Registry of Patients With Von WilLEbrand Disease Treated With Voncento®
Withdrawn NCT00630448 - Collection of Blood in Normal Subjects and Subjects With Von Willebrand Disease (VWD) N/A
Terminated NCT00387192 - A Study With OPTIVATE® in People With Von Willebrand Disease Phase 3
Completed NCT02973087 - rVWF IN PROPHYLAXIS Phase 3
Completed NCT01410227 - Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD) Phase 3
Completed NCT01949220 - Willebrand International Non-interventional Global Surveillance
Completed NCT01589848 - Study on Von Willebrand Disease and Hemophilia in Cuenca, Ecuador N/A
Completed NCT00941616 - Study of a pd VWF/FVIII Concentrate, Biostate®, in Subjects With Von Willebrand Disease Phase 2/Phase 3
Completed NCT00557908 - The Von Willebrand Disease (VWD) International Prophylaxis Study N/A
Active, not recruiting NCT04953884 - Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease VWD) Patients <6 Years of Age Phase 3